1MRK Stock Chart & Stats
€144.60
€2.80(1.97%)
At close: 4:00 PM EDT
€144.60
€2.80(1.97%)
Day’s Range― - ―
52-Week Range€96.00 - €192.00
Previous CloseN/A
Volume0.00
Average Volume (3M)336.00
Market Cap
€62.24B
Enterprise Value€56.15K
Total Cash (Recent Filing)€3.77B
Total Debt (Recent Filing)€12.04B
Price to Earnings (P/E)24.6
Beta0.66
Next Earnings
Aug 06, 2026EPS Estimate
2.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.82
Shares Outstanding129,242,250
10 Day Avg. Volume400
30 Day Avg. Volume336
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€137.80Price Target Upside-4.70% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)8.03
Revenue Forecast (FY)€21.15B
Bulls Say, Bears Say
Bulls Say
Durable Margins And ProfitabilityConsistently strong gross and EBITDA margins indicate structural pricing power and efficient core operations across divisions. Durable margins provide a buffer in downturns, fund R&D and capex, and support long-term reinvestment without immediate reliance on external financing.
Diversified, Recurring Business ModelA three‑pillar business model spreads revenue across Healthcare, recurring Life Science consumables/services, and Electronics specialty materials. Diversification reduces reliance on any single cycle, supports steady cash flows, and raises barriers to entry through customer qualification and regulatory links.
Manageable Leverage And Resilient Balance SheetModerate, improving leverage leaves room for strategic investment, dividend support, or opportunistic M&A without overburdening interest coverage. A stronger equity base and controlled debt improve financial flexibility and reduce refinancing risk across business cycles.
Bears Say
Softening Revenue TrendNear‑term top‑line weakness and a sharply negative TTM trend suggest slowing end‑market demand or portfolio headwinds. Sustained revenue weakness can erode operating leverage, reduce funds available for innovation, and pressure long‑term growth unless addressed by new product or market expansion.
Returns On Equity Have CooledA material decline in ROE indicates the company is generating less profit per unit of shareholder capital than in prior years. Persistently lower returns can signal competitive pressure, capital intensity, or margin compression, making it harder to justify reinvestment without efficiency gains.
Only Moderate Cash ConversionFree cash flow improvements exist, but cash conversion remains moderate versus earnings. This limits internal funding for R&D, capex, and strategic M&A, and increases sensitivity to working capital swings, reducing buffer against extended downturns or larger strategic investments.
1MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €96.00 and its highest was €192.00 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €62.24B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Merck KGaA’s earnings last quarter?
Currently, no data Available
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Overvalued.
Does Merck KGaA pay dividends?
Merck KGaA does not currently pay dividends.
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.05.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in IT:1MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.96%
12-Months-Change
Fundamentals
Return on Equity
1.53%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
1MRK Stock 12 Month Forecast
Average Price Target
€137.80
▼(-4.70% Downside)
Technical Analysis
Evotec
―
Fresenius SE & Co. KGaA
―
Sartorius
―
Dermapharm Holding SE
―
Siemens Healthineers AG
―